Phil Vickers talks new role as head of Longwood’s Solu after Faze shutdown; Regeneron CFO to retire in February

Phil Vickers started last week as president and CEO of Solu Therapeutics, a Longwood Fund startup developing small molecule-antibody chimeras.

He takes the place of Longwood executive partner David Donabedian, who has taken the early CEO roles at a number of companies Longwood has backed, including Axial Therapeutics, ImmuneID and DEM BioPharma.

Vickers was previously head of Faze Medicines, a condensates biotech started by Third Rock that launched with $81 million in 2020 before shutting down at the end of last year.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。